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Despite several decades of intensive effort to improve the imaging techniques for lung cancer diagnosis and
treatment, primary lung cancer is still the number one cause of cancer death in the United States and worldwide.
The major causes of this high mortality rate are distant metastasis evident at diagnosis and ineffective treatment for
locally advanced disease. Indeed, approximately forty percent of newly diagnosed lung cancer patients have distant
metastasis. Currently, the only potential curative therapy is surgical resection of early stage lung cancer. Therefore,
early detection of lung cancer could potentially increase the chance of cure by surgery and underlines the
importance of screening and detection of lung cancer. In the past fifty years, screening of lung cancer by chest
X-Ray (CXR), sputum cytology, computed tomography (CT), fluorescence endoscopy and low-dose spiral CT (LDCT)
has not improved survival except for the recent report in 2010 by the National Lung Screening Trial (NLST), which
showed a 20 percent mortality reduction in high risk participants screened with LDCT compared to those screened
with CXRs. Furthermore, serum biomarkers for detection of lung cancer using free circulating DNA and RNA,
exosomal microRNA, circulating tumor cells and various lung cancer specific antigens have been studied extensively
and novel screening methods are being developed with encouraging results. The history of lung cancer screening
trials using CXR, sputum cytology and LDCT, as well as results of trials involving various serum biomarkers, are
reviewed herein.Introduction
Cancer is the leading cause of death worldwide and
accounted for 7.6 million deaths in 2008 with primary
lung cancer responsible for 1.37 million deaths alone [1].
There are an estimated 226,160 new cases of lung cancer
in 2012 in the United States with approximately 160,340
deaths [2]. The lack of sensitive screening tests for early
detection of lung cancer plus ineffective treatment for
locally advanced and metastatic disease is responsible
for the high mortality rate and the dismal overall five
year survival rate [3,4]. With the extensive effort for
tobacco awareness education, advancements of imaging
and combined treatment modalities, the 5-year survival
rate of lung cancer has improved marginally from 12%
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reproduction in any medium, provided the ordetected at an early stage, complete resection of the
tumor may produce a 5-year survival approaching 67%
[5]. Therefore early detection of lung cancer by sensitive
screening tests could be an important strategy to im-
prove the prognosis of lung cancer.
The results of primary lung cancer screening trials
using imaging modalities such as chest X-RAYs com-
bined with sputum sampling, CT scans and LDCT will
be reviewed. In addition, the role of serum biomarkers
and biological modalities, circulating DNA and RNA,
exosomal microRNA and circulating tumor cells (CTCs)
and thermogram and nanopore sensor technologies will
be discussed.
History of lung cancer screening with chest X-ray
The first large prospective trial using chest X-Ray as a
screening tool for the early detection of lung cancer was
performed in the UK and published in 1968. In that
study there were 29723 men aged 40 years or older who
had six-monthly chest radiograph screening for three
years compared with a control group of 25311 men who
received chest radiograph at the beginning and the endtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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differ statistically in the two groups, with 62 deaths in
the screened group and 59 in the control group, but the
5-year survival rate for participants with lung cancer
diagnosed by screening chest radiographs was 23% ver-
sus 6% in the control group [6,7].
Chest X-ray and sputum cytology
There are four randomized trials integrating CXR with
sputum cytology. The first three trials were sponsored in
the United States by the National Cancer Institute
(NCI): the Mayo Lung Project (MLP), the Johns Hopkins
Lung Project (JHLP), and the Memorial Sloan-Kettering
Lung Project (MSKLP) [8-10].
The MLP randomized 9211 participants from 10,933
high risk men aged 45 years or older to CXR and spu-
tum cytology annually as the control group versus CXR
and sputum cytology every 4 months in the screening
group for 6 years. The study reported that there were
206 cases of lung cancer diagnosed in the screening
group and 160 cases in the control group, with signifi-
cantly earlier stages of lung cancer diagnosed in the
screening group and an improved 5-year survival. How-
ever, the trial did not show any statistical disease-specific
mortality difference between the two study groups from
lung cancer with follow-up over 20 years [8,11,12].
The MSKLP and the JHLP trials randomized partici-
pants aged 45 or older to annual CXR with (screening
group) or without (control group) sputum cytology ana-
lysis every 4 months. The MSKLP study enrolled a total of
10,040 subjects and diagnosed 144 lung cancer cases in
both groups but there was no difference in stage distribu-
tion, overall survival or disease specific mortality between
the two groups [10,13]. The JHLP study randomized
10,386 participants and noted 194 cases of lung cancer in
the screening group compared to 202 cases in the control
group. Akin to the MSKLP trial, the final results of JHLP
showed no differences in overall survival or disease-
specific mortality between the study groups [14-16].
A Czechoslovakian trial randomized 6364 high-risk
participants aged 40 or older to CXR and sputum cy-
tology every 6 months for 3 years as the screening group
versus CXR and sputum cytology at the beginning and
the end of 3 years in the control group [17]. There were
39 cases of lung cancer in the screening group versus 27
cases in the control group. However, there was no differ-
ence in disease-specific mortality between the two
groups at follow-up of 20 plus years [18].
From the aforementioned results of five randomized
trials, screening with CXR with or without sputum cy-
tology failed to reduce disease-specific mortality from
lung cancer in high risk populations. Nonetheless, in
1993 another large multicenter NCI-sponsored clinic
trial, the Prostate, Lung, Colorectal and Ovarian (PLCO)Cancer Screening Trial, randomized 154,901 individuals
aged 55 to 74 to receive annual CXR for 3 years or
standard medical care as controls. The screening ended
in 2006 and the final results showed that there were
1213 lung cancer specific deaths in the screening group
versus 1230 in the control population. There was no dif-
ference in terms of stage and histology [19].CT scan and lung cancer screening
Due to the high cost and false-positive results causing
over-diagnosis and treatment, CT scanning was not initially
considered to be a useful screening test for cancer detec-
tion. However, advances in imaging technology and the de-
velopment of fast LDCT have renewed interest in CT
scanning as a potential effective screening test for early de-
tection of lung cancer. Pilot studies using LDCTconducted
in New York [20,21] and Japan [22] for lung cancer screen-
ing reported that stage I lung cancer was detected in 80-
90% of newly diagnosed cases. Such encouraging results
warrant further clinic trials using LDCT as a screening tool
for lung cancer detection in high risk individuals.LDCT and lung cancer screening
There have been several uncontrolled LDCT screening
studies for lung cancer since 1992 (Table 1). The first
study was conducted in Japan and compared LDCT with
CXR for lung cancer screening in a high-risk population
[23]. This study enrolled 1369 high-risk individuals to
receive CXR and LDCT scans twice a year. The study
showed that there were 15 cases of lung cancer detected
by LDCT, but only 4 cases of the 15 were detected by
CXR. Among the 15 cases of lung cancer, 14 (93%) were
stage I and the mean tumor size was 1.6 centimeter [24].
In an update of that study, the five year survival rates for
lung cancers detected by initial and repeated LDCT
screening were 76.2% and 64.9%, respectively.
The second large uncontrolled study was also done in
Japan [25,26] and enrolled 5483 participants aged 40 to 74
to annual LDCT with annual sputum cytology and 3967
participants also had CXR. The results showed that 63
lung cancers were diagnosed and 57 of them were
detected by LDCT alone. Fifty one (89.5%) of the 57 cases
were stage I. Ten year survival of the 59 lung cancers
detected by LDCT screening was estimated at 86.2% [27].
The third non-randomized trial, the New York Early
Lung Cancer Action Project (ELCAP) [21], recruited 1000
asymptomatic smoking participants aged 60 or over to
evaluate annual LDCT scan as a screening test for lung
cancer compared with X-Ray. There were 27 lung cancer
cases detected by LDCT but CXR only diagnosed 7 of the
27 lung cancer cases observed by LDCT. Twenty three
(85%) of the lung cancers were stage I by LDCT whereas
CXR only detected four stage I lung cancer (14.8%).
Table 1 LDCT in lung cancer screening
Trial Name Study
design
No.
recruited
Characteristics of participants Exsmoker
quit (yrs)
Year
started
Report
date
LC baseline
rate (LDCT)
Stage I
Cancer at
Baseline
Age Sex Smoker(PkYr)
NLST [47] LDCT vs CXR 53454 55–74 M/F >=30 <15 2002 2011 1.0% 63.0%
NELSON [42,95] LDCT vs UC 15822 50–75 M/F 15–18.75 <10 2003 2016 0.9% 63.9%
ITALUNG [39] LDCT vs UC 3206 55–69 M/F >=20 <10 2004 NR 1.5% 47.6%
DEPISCAN [38] LDCT vs CXR 765 50–75 M/F >=15 <15 2002 2006 2.38% 0.9%
DANTE [37,96] LDCT vs UC 2472 60–74 M >=20 <10 2001 2007 2.2% 57%
DLCST [97] LDCT vs UC 4104 50–70 M/F >=20 <10 2004 2016 0.8% 58.8%
LSS [34,36] LDCT vs CXR 3318 55–77 M/F >=30 <10 2000 2005 1.9% 53.3%
LDCT= low-dose computed tomography; CXR=chest X-ray; NC=usual care; M=male; F=female; PkYr=packs/year; yrs=years; f/u=follow-up; NR=not reported;
LC=lung cancer.
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and included 1520 participants aged 50 or over with at
least a 20 pack-year history of smoking who underwent
annual LDCT and sputum cytology for five years. The
results showed that 17 of 28 non-small cell lung cancer
cases detected were stage I and mean tumor diameter
was 14.4 mm [28-30]. However, there was no difference
in lung cancer related mortality rates between this study
and the Mayo Lung Project in age and sex matched sub-
set analysis.
In 2006, Henschke et al., of ELCAP published the
results of an international collaboration (I-ELCAP), in
which 31567 high-risk asymptomatic participants aged
40 or over underwent LDCT screening from 1993 to
2005 at intervals of 7 to 18 months [31]. A total of 484
lung cancer cases were diagnosed (405 initial, 74 at fol-
low-up, 5 interval cancers). Among those 484 cases, 412
cases were stage I with an estimated 10 year survival rate
of 88% compared to 80% for all lung cancer patients.
The survival rate of 302 patients with stage I lung cancer
detected by LDCT screening undergoing surgical resec-
tion was 92%. The study results were encouraging but
the study was criticized because of funding sources from
a tobacco company [32]. Other important issues were
lead-time bias and over-diagnosis bias due to the slowly
progressive nature of stage I lung cancer as well as the
seemingly short 40 months median follow-up and less
than 20% of them followed for more than 5 years.
In response to the I-ELCAP results, Bach et al., [33]
reviewed the results of three uncontrolled LDCT screen-
ing trials conducted at Instituto Tumori in Milan,Italy,
the Moffitt Cancer Center in Tampa, FL, and the Mayo
Clinic, Rochester, MN in which 3246 asymptomatic,
high-risk participants underwent at least three annual
LDCT screenings and had a median follow-up of 3.9
years. The results showed that 144 lung cancers were
detected by LDCT screening compared with 44.5 cases
expected, which is more than a three-fold increase in the
number of newly-diagnosed lung cancer cases. Among144 cases, there were 96 (78%) stage I/II non-small cell
lung cancers. However, there was no significant decrease
in lung cancer related mortality rates, with 38 deaths
due to lung cancer in the trials compared with 38.8
deaths predicted. In addition there was no decrease in
the number of advanced lung cancers diagnosed with 42
individuals compared to 33.4 predicted.Randomized controlled trials using LDCT for lung
cancer screening
Compared with non-randomized studies, randomized
controlled trials (RCTs) are ideal studies to detect a real
benefit of any screening modality in terms of differen-
ces in mortality and recurrence of disease by comparing
screening group with controlled group and to avoid lead
time and length bias and overdiagnosis.
Nine randomized controlled trials evaluating LDCT to
screen lung cancer are ongoing worldwide [34-45]. [46]
The Lung Screening Study (LSS) was initiated in 2000,
whereas the NLST published the first trial results [47]
showing a relative 20% reduction in lung cancer specific
deaths among participants screened with LDCT versus
CXR. The NLST trial in 2002 recruited 53,454 high-risk
participants aged 55 or older to undergo three screenings
at 1-year intervals with either LDCT or CXR. The LDCT
group noted 247 lung cancer deaths per 100,000 person-
years compared to 309 deaths in the CXR group. The
NLST trial was acclaimed as a major breakthrough in the
lung cancer screening field and showed clear evidence of a
significant reduction in lung cancer deaths, but raised
concerns regarding how to define the high-risk popula-
tions and who would benefit from LDCT screening; what
is the optimal time to start LDCT screening; how long to
follow patients and what intervals to screen; and lastly the
overwhelming financial cost of LDCT screening. Time
and further research may provide definitive answers
regarding the impact of LDCT screening on lung cancer
specific mortality at the population level. Additional
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these questions and validate the NLST results.
The National Comprehensive Cancer Network (NCCN)
published Lung Cancer Screening Guidelines [48], recom-
mending annual LDCT screening for high-risk individuals
aged 55 to 74 who quit smoking less than 15 years with at
least a 30 pack-year smoking history. The guidelines sug-
gested algorithms to evaluate lung lesions such as solid
nodules of different size and ground glass opacities and at
what intervals, but uncertainties concerning the duration
of follow up and at what age to stop remains to be
addressed. Nonetheless, this is the first lung cancer
screening recommendation attempting to reduce lung
cancer related mortality.
Serum biomarkers and screening for lung cancer
Currently, there are no validated biomarkers for early
lung cancer detection. Extensive efforts have been made
for the development of useful biomarkers and novel bio-
markers from recent studies will be discussed here.
Circulating tumor cells (CTCs)
CTCs are circulating and free floating malignant cells
that have migrated from the primary cancer or meta-
static sites in the peripheral blood. Advanced techniques
have been developed to identify, isolate and characterize
these CTCs [49]. Different from traditional invasive pro-
cedures like biopsies, CTCs represent a potentially easy
source of tumor tissue for diagnosis, characterization
and monitoring of solid tumors. CTCs have been evalu-
ated as a surrogate metastatic marker for primary lung
cancer [50]. The CTC-chip, an innovative micro-device
developed at Harvard, proved feasible to identify and
isolate CTCs in the blood of metastatic lung cancer
patients [51]. Further studies to confirm the clinical
value of CTCs in the early detection, characterization
and monitoring of lung cancer are ongoing.
Free circulating DNA
In 2003, Sozzi et al., published a case–control study
demonstrating that the quantity of free circulating DNA
can be measured in lung cancer patients by real-time
quantitative polymerase chain reaction (RT-PCR) of the
human telomerase reverse transcriptase gene (hTERT)
[52]. Subsequently Sozzi et al., designed a 5-year pro-
spective trial that enrolled 1,035 heavy smokers aged 50
years or older who were monitored by annual LDCT for
5 years and plasma circulating DNA levels were mea-
sured by RT-PCR. The authors reported no improve-
ment in the accuracy of lung cancer screening by LDCT
in heavy smokers by measurement of the baseline assess-
ment of plasma circulating DNA level, but higher levels
of plasma circulating DNA at surgery was a risk factor
for aggressiveness of lung cancer with a decreased5-year survival [53]. They hypothesized that only rapidly
growing lung cancers would be able to produce a suffi-
cient amount of plasma circulating DNA to be sensitive
as a marker. In addition, others have noted that free
circulating DNA measured by human hTERT gene is not
specific for lung cancer and that the level of free
circulating DNA may be influenced by other benign dis-
eases [54].
Plasma proteomics
Abundant proteins in the plasma are an underutilized
source with valuable information for clinical usage [55].
Chairs et al., studied the thermal properties of plasma
by highly sensitive differential scanning calorimetry
(DSC) which can generate unique and statistically differ-
ent DSC thermograms in several diseases, such as SLE,
Lyme disease, and rheumatoid arthritis or cancers in-
cluding cervical, lung, melanoma, ovarian, and uterine
[56-60]. In Xiang et al., a case–control study [61] involv-
ing 20 patients with early stage lung cancer and 100
healthy volunteers, DSC thermograms from patients
with lung cancer generated a unique characteristic
thermogram that differed statistically from healthy con-
trols and suggested that DSC was sensitive to properties
of plasma proteins other than their charge and mass.
Such studies hypothesized that characteristic thermo-
gram changes in shape and position in lung cancer can
arise from changes in the concentrations of different
plasma proteins, including tumor antigens, from cancer-
related protein-protein interactions, or cancer-secreted
peptides binding to other plasma proteins. In a subse-
quent study [62] of 30 patients with early stage lung can-
cer and 109 healthy controls, the authors validated their
hypothesis and suggested that early stage lung cancer
may have a characteristic signature thermogram profile
that may serve as a biomarker for the diagnosis of lung
cancer. A large scale clinical study is on-going to further
characterize the sensitivity and specificity of this assay.
Exosomal microRNA
The discovery of tumor-derived exosomes was first
reported in the peripheral blood of ovarian cancer
patients in 1979 [63,64]. Exosomes are small membrane
vesicles containing common proteins generic to all exo-
somes as well as tumor associated proteins (antigens)
unique to their origin [65]. Tumor cells can secrete ele-
vated levels of exomes containing tumor antigens (Her2/
Neu and gp100), which can be detected in serum, malig-
nant effusions and ascites [66,67]. Ratajczak et al., [68].
showed that horizontal transfer of exosome associated
mRNA may play a key role in signal transduction lead-
ing to cell proliferation. Further studies by Valadi et al.,
[69,70]. reported that both cellular mRNA and micro-
RNA can be carried by exosomes to remote target cells
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Based on these correlations, Taylor et al., [71]. reported
that patients with ovarian cancer demonstrated unique
exosomal microRNA patterns which were characteristic-
ally different from the pattern from healthy controls,
which suggested that cancer specific microRNA within
exosomes may be useful as a putative diagnostic bio-
marker for early detection of cancer.
Based on evidence that specific microRNA profiles are
unique to different types of cancers [72], Rabinowits
et al., [73]. designed a case–control study and enrolled
27 patients with various stages of lung adenocarcinoma
and 9 healthy controls, and evaluated the concentration
of exosomes and microRNA. The authors reported that
the mean exosome concentration was 4 times higher in
the lung adenocarcinoma group (2.85 mg/mL) compared
to the control group (0.77 mg/mL). The mean microRNA
concentration was 2.3 times higher in the lung adenocar-
cinoma group (158.6 mg/mL) versus the control group
(68.1 mg/mL). A significant difference in exosome and
miRNA concentration between lung cancer patients and
controls suggest that circulating exosomal microRNA
might be a useful biomarker for early detection of lung
cancer.
Nanopore sensor
In the last twenty years, various sensitive quantitative
techniques have been developed to detect and analyze
macromolecules at a single molecular level in biomedical
research [74]. With increased understanding of short
tumor-specific microRNAs playing a regulatory role in
tumor cell proliferation and differentiation and an asso-
ciation between specific microRNA profiles with differ-
ent types of cancers, detecting microRNA by utilizing
highly sensitive single-molecular assays such as fluores-
cence correlation spectroscopy [75], nanoparticles and
single-molecule fluorescence [74] showed diagnostic po-
tential for clinic application for the early detection of
cancer and monitoring response to treatment. In order
to avoid complicated chemical labeling with fluorescence
dye and target amplification by the aforementioned
assays, Wang et al., [76] described an α-haemolysin pro-
tein based nanopore sensor technology to detect micro-
RNAs at the molecular level from blood samples in six
lung cancer patients without amplification via micro-
RNAs. The nanopore sensor is capable of detecting sin-
gle nucleotide difference with let-7 microRNAs. This
strategy may be used in concert with unique lung cancer
microRNA profiles for lung cancer screening and/or
monitoring treatment responses in lung cancer patients.
Telomerase
Telomerase, a ribonucleoprotein complex with reverse
transcriptase activity to synthesis DNA termini at theend of eukaryotic chromosomes during each cell div-
ision, plays a vital role in the replication of chromosomal
termini or telomeres. It is inactivated in most normal
tissues at an undetectable level and reactivated or upre-
gulated in all cancer tissues investigated, such as breast,
prostate, lung, liver, and pancreatic cancer [77-79]. Com-
pared to other cancer markers, the level of telomerase
activity may be increased gradually from very early
tumorigenesis and can be detectable even before cancer
patients experience any symptoms [80], which suggests
that telomerase activity maybe a useful biomarker for
the early detection of cancer.
Miyazu et al., [81]. evaluated telomerase protein ex-
pression in normal bronchial epithelia among 206 high-
risk lung cancer individuals in which bronchoscopy was
performed every 3 to 6 months. Fifteen lesions were
detected in 12 patients. Human telomerase reverse tran-
scriptase was measured and 11 of the 15 lesions that
were telomerase negative did not develop lung cancer
after photodynamic therapy whereas 4 of the 15 lesions
that were positive for telomerase progressed to lung can-
cer. Such findings suggest that telomerase activity may
be a useful biomarker for detection of lung cancer whose
telomerase activity is upregulated in early stages of can-
cers or pre-cancerous cells. Further well-designed clin-
ical studies are needed to help elucidate the role of
telomerase in tumorigenesis and validate the role of tel-
omerase as a biomarker.
Circulating RNA
Aberrant mRNA expression from normal genes has also
been investigated in association with tumorigenesis.
Using reverse transcription polymerase chain reaction
(RT-PCR), studies have demonstrated the detection of
tyrosinase mRNA in whole blood samples of melanoma
patients [82] and telomerase RNA in the serum from
breast cancer patients [83]. These results prompted
investigators to explore the use of circulating RNA as a
biomarker for detection of lung cancer. The translational
production of circulating 5T4 mRNA is a trophoblast
glycoprotein present in epithelial malignancies and is a
potential biomarker for cancer detection. Kopreski et al.,
[84]. evaluated serum for 5T4 mRNA in 5 patients with
breast cancer, 14 patients with non-small-cell lung can-
cer and 25 normal controls. The circulating 5T4 mRNA
was detected in 42% of cancer patients (8/19) and 12%
of normal controls (3/25). These results demonstrate
that circulating mRNA may be a biomarker for early
lung cancer diagnosis.
Miscellaneous biomarkers
There are several other molecular candidates that have
been used as biomarkers. The LunX (lung-specific X pro-
tein) is a human lung-specific gene identified in 2001 [85].
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pressed in 14 of 24 (58%) blood samples from NSCLC
patients [86]. Cytokeratin 19 is an acidic subunit
expressed in carcinoma cells as well as on normal epithelia
whereas CYFRA21-1 is a cytokeratin 19 fragment in the
sera of patients with lung cancers. CYFRA21-1 has been
studied extensively and one study recruited 104 patients
with malignancies and 42 healthy controls and showed
that CYFRA21-1 was overexpressed in 86% of malignant
cases, especially in lung cancer (9 of 16 cases) [87].
Using fluorescent microsatellite analysis, Beau-Faller
et al., evaluated DNA microsatellite in 34 patients with
lung cancer, including 11 patients with small cell lung
cancer (SCLC) and 23 patients with NSCLC and 20
healthy controls. A panel of 12 microsatellites was
selected to perform allelotyping. Plasma DNA allelic im-
balance (AI) was noted in 88% of cancer patients (30/34)
compared to no plasma or bronchial DNA alteration in
20 healthy controls [88].
Discussion
Decades of research have evaluated various approaches
for lung cancer screening, including routine chest radio-
graph, sputum cytology, CT scanning, LDCT and, most
recently, molecular biomarkers. Early screening tests of
high risk individuals based on sputum cytology or chest
X-Ray have not shown improvement in disease-specific
survival. Chest LDCT scan has been proven as an ef-
fective tool for the detection of early stage resectable
disease. Indeed, results from the NLSCT showed a 20
percent mortality reduction in high-risk participants
screened with LDCT compared to those with chest X-
Rays. Recent NCCN guidelines endorse LDCT as a
screening tool for lung cancer. However, questions re-
main regarding the definition of high risk patients; how
long and how frequent to screen; and how to address
the false positive results and high cost and potential tox-
icity from radiation exposure. Additional randomized
trials using LDCT are ongoing and will address these un-
answered questions and may eventually demonstrate the
real impact of early detection on mortality at a popula-
tion level.
Several serum tumor protein markers have been stud-
ied extensively, and are currently available for blood
testing, such as carcinoembryonic antigen, serum cyto-
keratin 19 fragment, and progastrin-releasing peptide,
but none of them is satisfactory for diagnosis of early
stage lung cancer because of their relatively low sensitiv-
ity and specificity in detecting the presence of cancer
cells [89-91]. Different and innovative approaches must
be explored to tap the wealth of serum tumor pro-
tein pools like DSC thermogram profiling for earlier
detection of lung cancer, which appears promising
according to case control study results.With the advances of our understanding of key cellular
changes of lung cancer and the rapid development of new
technologies, recent diagnostic approaches have focused
on genomics and proteomics. The Human Genome Project
(HGP) announced the first working draft in 2000 and
opened the genomic era, which has provided opportunities
for gene expression analysis and several studies have iden-
tified differences in gene expression between normal and
lung cancer cells using techniques such as serial analysis of
gene expression [92] and cDNA microarray [93,94].
Researchers have been studying tumorigenesis, target-
ing subtle changes at the molecular level to facilitate
early diagnosis, identify clinically relevant biological trig-
gers related to cancer development, and identify useful
biomarkers. In this regard, CTCs, exosomal microRNA,
free circulating DNA, telomerase, LunX and CYFRA21-
1 have demonstrated encouraging results. Investigators
have taken advantage of technical advances that allow
rapid high-throughput assays to interrogate the genome,
proteome, and epigenome. Results of such Phase I stud-
ies are expected to be reported in 2012.
Based on screening guidelines suggested by the NCCN,
significant strides have been made in effective screening
methods todiagnosis lungcancer at early stages forhigh risk
patientswitha30pack-year smokinghistory.Butchallenges
in early detection of lung cancer remain. As one can antici-
pate, in the near future, effective biomarkers or evidence-
basedimagescansusedaloneorincombinationmayprovide
theclinicianwitheffectivetoolsfortheearlydetectionoflung
cancerintheeraofmolecularanddigitaloncology,andhope-
fully alter the natural course of lung cancer and improve the
survivalofpatientswithlungcancer.
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